Get all your AEON Biopharma news in one place.

Sep 03, 2020

AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment

-Critical milestone transitions AEON Biopharma to clinical-stage company--Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021--Investment expected to provide funding for clinical programs…

Oct 08, 2019

AEON Biopharma Appoints Chris Carr as Chief Financial Officer and Scott Akamine as General Counsel

Biopharma Firm Continues to Build Industry Leading Management Team; Poised for Next Phase of Growth in Therapeutic Toxin Market NEWPORT BEACH, Calif., October 1, 2019 – AEON Biopharma, an emerging…

Sep 16, 2019

AEON Biopharma Appoints BOTOX® Therapeutic Head as President and Chief Executive Officer

Dynamic Industry Veteran Led Multi-Billion Dollar Therapeutic Neurotoxin Portfolio NEWPORT BEACH, Calif., May 13, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive…